Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Westin · SciRah

Researcher profile · Semantic Scholar

J. Westin

Share profile

J. Westin — researcher profile on SciRah

h-index: 15
Works: 131
Citations: 1,064

Most-cited papers

Five Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-cell Lymphoma: Results from the US Lymphoma CAR T Consortium
M. Jain, J. Spiegel, L. Nastoupil, J. Tamaresis +28 more
2024Journal of Clinical Oncology69 citations Open access
Semantic Scholar
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma
M. Roschewski, D. Kurtz, J. Westin, R. Lynch +14 more
2025Journal of Clinical Oncology35 citations Open access
Semantic Scholar
Large B cell lymphoma microenvironment archetype profiles (LymphoMAPs)
Xu-Bin Li, K. Singhal, Q. Deng, Dai Chihara +28 more
2025Cancer Cell29 citations Open access
Semantic Scholar
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
L. Budde, Hui-Lai Zhang, Won-Seog Kim, Dai Maruyama +24 more
2025Journal of Clinical Oncology28 citations Open access
Semantic Scholar
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial
J. Gunther, Jie Xu, M. Bhutani, P. Strati +23 more
2024The Lancet Haematology28 citations Open access
Semantic Scholar
The future of immunotherapy for diffuse large B‐cell lymphoma
J. Duell, J. Westin
2024International Journal of Cancer27 citations Open access
Semantic Scholar
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma
Yi-Bo Dai, A. Kizhakeyil, Dai Chihara, Xu-Bin Li +17 more
2025Nature Genetics25 citations Open access
Semantic Scholar
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
J. Westin, T. Phillips, Amitkumar Mehta, Marc S Hoffmann +13 more
2025Blood Advances18 citations Open access
Semantic Scholar
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.
C. Pinnix, B. Dabaja, J. Gunther, P. Fang +14 more
2024JAMA Oncology18 citations Open access
Semantic Scholar
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
R. Maziarz, Michael R. Bishop, Constantine S. Tam, P. Borchmann +30 more
2025Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
G. S. Manzar, C. Pinnix, S. Dudzinski, K. Marqueen +18 more
2025Frontiers in Immunology15 citations Open access
Semantic Scholar
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma
P. Strati, Lei Feng, A. Tyshevich, D. Shavronskaya +15 more
2025Clinical Cancer Research13 citations
Semantic Scholar
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy
James Long, Rishab Prakash, P. Edelkamp, M. Knafl +19 more
2025JAMA Network Open12 citations Open access
Semantic Scholar
ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
J. Westin, A. Herrera, Ryan C. Lynch, J. Abramson +30 more
2024Blood11 citations
Semantic Scholar
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas
D. Chihara, Raphael Steiner, R. Nair, Lei Feng +16 more
2025Blood Advances10 citations Open access
Semantic Scholar
Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience
R. Nair, Iyanuoluwa Ogundipe, J. Gunther, L. Medeiros +29 more
2023Blood10 citations Open access
Semantic Scholar
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
J. Westin, Olalekan O. Oluwole, M. J. Kersten, David B. Miklos +16 more
2023Hematological Oncology10 citations Open access
Semantic Scholar
Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
J. Westin, R. Steiner, D. Chihara, Sairah Ahmed +19 more
2023Blood8 citations Open access
Semantic Scholar
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
P. Strati, Lei Feng, J. Westin, R. Nair +15 more
2025Nature Communications7 citations Open access
Semantic Scholar
primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma
J. Westin, L. Fayad, Raphael Steiner, Sairah Ahmed +21 more
2025Blood6 citations
Semantic Scholar
Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
M. Lunning, Hailin Wang, Zhen-Huan Hu, F. Locke +19 more
2024American journal of hematology/oncology5 citations Open access
Semantic Scholar
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement
Anath C. Lionel, A. Gurumurthi, A. Fetooh, Rami W. Eldaya +12 more
2024Leukemia and Lymphoma5 citations
Semantic Scholar
Abstract CT037: A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma
P. Strati, Lei Feng, D. Chihara, J. Westin +8 more
2024Cancer Research5 citations
Semantic Scholar
Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
Arnaud Amzallag, T. Basavanhally, J. Westin, Marc S. Hoffmann +8 more
2024Blood5 citations
Semantic Scholar
Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).
Romil D Patel, A. Gurumurthi, Lei Feng, J. Westin +16 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Kunhwa Kim, D. Chihara, L. Fayad, S. Neelapu +12 more
2024Blood5 citations
Semantic Scholar
Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy.
G. S. Manzar, Susan Y. Wu, S. Dudzinski, E. Cha +17 more
2024International Journal of Radiation Oncology, Biology, Physics5 citations
Semantic Scholar
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Neha Akkad, Lei Feng, J. Westin, F. Hagemeister +17 more
2025Blood Advances4 citations Open access
Semantic Scholar
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
P. Strati, Amanda Brandt, Anath C. Lionel, J. Henderson +10 more
2025Journal for ImmunoTherapy of Cancer4 citations Open access
Semantic Scholar
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
C. Jacobson, J. Westin, David B. Miklos, Alex F. Herrera +10 more
2025Clinical Cancer Research3 citations Open access
Semantic Scholar
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
J. Westin, Julio Chavez, S. Schuster, V. Vučinić +19 more
2025Blood3 citations
Semantic Scholar
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU.
P. Rajendram, R. Stephens, Anne Rain T. Brown, Heather P. May +20 more
2025Critical Care Medicine3 citations
Semantic Scholar
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
J. Westin, Gary L. Simmons, N. Bartlett, Houston E. Holmes +15 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
Sushanth Gouni, Anath C. Lionel, Lei Feng, Charles Gaulin +19 more
2024Blood3 citations
Semantic Scholar
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
N. Gower, P. Feugier, J. Westin, Jean-Marc Schiano de Colella +38 more
2026Blood2 citations Open access
Semantic Scholar
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results
Marc S. Hoffmann, Julio Chavez, J. Westin, J. Jørgensen +17 more
2025Blood2 citations
Semantic Scholar
Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial
Mark P. Hamilton, A. Al Zaki, Lei Feng, Z. Hunzeker +9 more
2025Blood2 citations
Semantic Scholar
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results
Grzegorz Nowakowski, Marc S. Hoffmann, Javier L. Munoz, J. Westin +11 more
2025Blood2 citations
Semantic Scholar
Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma
F. Locke, J. Westin, Christina To
2025Future Oncology2 citations Open access
Semantic Scholar
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results
Julio Chavez, J. Westin, Javier L. Munoz, E. Bachy +13 more
2025Blood2 citations
Semantic Scholar
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
Yuan Tian, J. Budka, Frederick L. Locke, J. Westin +7 more
2025Frontiers in Oncology2 citations Open access
Semantic Scholar
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
P. Fang, S. Noticewala, Susan Y. Wu, J. Gunther +16 more
2024Advances in Radiation Oncology2 citations Open access
Semantic Scholar
Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
P. Jain, Young-Ok Chi, J. Westin, H. Hill +29 more
2024Blood2 citations
Semantic Scholar
Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study
P. Strati, Lei Feng, J. Westin, R. Nair +13 more
2023Blood2 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
J. Westin, C. Jacobson, J. Chavez, A. Sureda +16 more
2023Hematological Oncology2 citations Open access
Semantic Scholar
Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions.
J. Westin, Shimere Sherwood, Karen Hagerty, J. Gralow
2025JCO Oncology Practice1 citations
Semantic Scholar
Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study
Hun Lee, G. Ravizzini, J. Wixom, Ayushi Chauhan +8 more
2025Blood1 citations
Semantic Scholar
Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma
R. Shah, R. Lin, A. Mason, L. Johnson +11 more
2025Blood1 citations
Semantic Scholar
First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study
John M. Burke, N. Bartlett, Gary L. Simmons, L. Fitzgerald +20 more
2025Blood1 citations
Semantic Scholar
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019
Zhiping Luo, Meng Li, B. Primeaux, R. Shah +7 more
2025Blood Advances1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Neelapu×23
Invite
S. Neelapu — researcher profile on SciRah
Sairah Ahmed×22
Invite
Sairah Ahmed — researcher profile on SciRah
P. Strati×20
Invite
P. Strati — researcher profile on SciRah
L. Nastoupil×17
Invite
L. Nastoupil — researcher profile on SciRah

×16

Invite

D. Chihara — researcher profile on SciRah

Invite

Lei Feng — researcher profile on SciRah

Invite

S. Iyer — researcher profile on SciRah

Invite

L. Fayad — researcher profile on SciRah

Invite

L. Malpica — researcher profile on SciRah

Invite

C. Flowers — researcher profile on SciRah

Invite

C. Flowers — researcher profile on SciRah

Invite

R. Nair — researcher profile on SciRah